Keytruda® (pembrolizumab) – New indication
January 27, 2023 - Merck announced the FDA approval of Keytruda (pembrolizumab), as a single agent, as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung cancer (NSCLC).
Top